Fig. 4

Ex vivo anti-CD49d antibody treatment preferentially blocks migratory responses of DMD-derived CD49d^hi T cells. Blocking effects of the anti-CD49d mAb upon transendothelial (a) and fibronectin-driven migration (b) of CD49d^lowCD4⁺ or CD49d^hiCD4⁺ and CD49d^lowCD8⁺ or CD49d^hiCD8⁺ T cells from DMD patients. Control Ig-treated cells were taken as 100 % of migratory/adhesive responses. c Adhesion onto myotubes of CD49d^hiCD4⁺ and CD49d^hiCD8⁺ T cells from DMD patients and healthy controls following treatment with anti-CD49d mAb or control Ig. *p < 0.05, **p < 0.01, ***p < 0.001